Bausch Health Companies Inc. Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax
Bausch Health Companies Inc. (BHC) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-20.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax · last filed 2019-02-20
- Bausch Health Companies Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2018 was $0.00.
- Bausch Health Companies Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2017 was -$1.00M.
- Bausch Health Companies Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2016 was -$1.00M.
- Bausch Health Companies Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2014 was -$5.00M.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 12 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 12 month as first filed |
|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-20 | |
| 2017-12-31 | -$1.00M 10-K · filed 2019-02-20 | |
| 2016-12-31 | -$1.00M 10-K · filed 2019-02-20 | |
| 2015-12-31 | $1.00M 8-K · filed 2018-08-10 | $600.00K 10-K · filed 2016-04-29 |
| 2014-12-31 | -$5.00M 10-K · filed 2017-03-01 | -$5.20M 10-K · filed 2015-02-25 |
| 2013-12-31 | -$200.00K 10-K · filed 2016-04-29 | -$210.00K 10-K · filed 2014-02-28 |
| 2012-12-31 | $0.00 10-K · filed 2015-02-25 | $27.00K 10-K · filed 2014-02-28 |
| 2011-12-31 | -$53.00K 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |